Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT01011075 · ClinicalTrials.gov registry record · Phase 2
Study of Gleevec and Weekly Paclitaxel in Patients Aged 70 or Older With Advanced Non-small Cell Lung Cancer
A Phase 2 study, sponsored by New Mexico Cancer Research Alliance.
- Completed
- Registry status
- Phase 2
- Development phase
- 34
- Enrollment target
NCT01011075: Completed Phase 2 study, sponsored by New Mexico Cancer Research Alliance.
NCT01011075 is a Phase 2 study that has completed, run by New Mexico Cancer Research Alliance. The registered enrollment target is 34 participants, below the 133-participant average among 30,622 other Phase 2 trials with a reported enrollment target (74% lower). According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT01011075, a Phase 2 study, has completed, sponsored by New Mexico Cancer Research Alliance.
- COMPLETED
- Registry status
- Phase 2
- Development phase
- 34 participants
- Enrollment target
Study Summary
This study will evaluate the clinical efficacy of combining Gleevec (imatinib mesylate), a PDGFR antagonist, with front-line, single-agent paclitaxel in a cohort of elderly patients with advanced, non-small cell lung cancer.
Primary Outcome
Response rates according to RECIST criteria (version 1.0) expressed as percentage of evaluable patients.
Interventions
- DRUG Paclitaxel
- DRUG Imatinib mesylate
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 34 participants |
| Start Date | 2009-08 |
| Est. Completion | 2012-07 |
| Phase | Phase 2 |
What the finished NCT01011075 record still lists
NCT01011075 is an interventional study that assigns participants to a tested intervention. The registry caps enrollment at 34 participants, a relatively small participant target, below the 133-participant average among 30,622 other Phase 2 trials with a reported enrollment target (74% lower).
The record links to 0 conditions, and to 2 interventions - of which Paclitaxel is the first listed.
NCT01011075 does not publish any study locations in the registry export this page uses.
Frequently Asked Questions
What is clinical trial NCT01011075 about?
NCT01011075 is a clinical study titled "Study of Gleevec and Weekly Paclitaxel in Patients Aged 70 or Older With Advanced Non-small Cell Lung Cancer". This study will evaluate the clinical efficacy of combining Gleevec (imatinib mesylate), a PDGFR antagonist, with front-line, single-agent paclitaxel in a cohort of elderly patients with advanced, non-small cell lung cancer.
What is the current status of trial NCT01011075?
This trial is currently completed. It is a Phase 2 study. The enrollment target is 34 participants. The study started on 2009-08. Estimated completion is 2012-07.
What interventions are being tested in trial NCT01011075?
The interventions under investigation include: Paclitaxel (DRUG), Imatinib mesylate (DRUG).
Who is sponsoring clinical trial NCT01011075?
This trial is sponsored by New Mexico Cancer Research Alliance, which has 66 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
How this trial's enrollment target compares
Where NCT01011075's enrollment target sits among peer trials
34 1539th of 2000 higher than 448 of 2,000 other Phase 2 trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Phase 2 trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT02897063 · 34 participants · Phase 1
Effects of Midodrine and Droxidopa on Splanchnic Capacitance in Autonomic Failure
- NCT03906617 · 34 participants · Phase 4
Bupivacaine/Epinephrine +Dexamethasone vs. Liposomal Bupivacaine
- NCT03992378 · 34 participants · NA
Neuromodulation to Regulate Inflammation and Autonomic Imbalance in Sepsis
- NCT04047849 · 34 participants · Phase 4
Latency Antibiotics in Previable PPROM, 18 0/7- 22 6/7 WGA
Similar registry start date
- NCT05988463 · started 2027-01-01 · Phase 1
Dose-Escalation Study of Artesunate Patients With IPF
- NCT07219706 · started 2026-12-10 · NA
Dietary Fiber and Time Restricted Eating
- NCT02831335 · started 2026-12-01
Technical Development of Multi-Parametric Renocerebral MRI
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia